Prophylaxis of post-myocardial infarction dysrhythmias by long-term timolol therapy

Abstract The antiarrhythmic efficacy of timolol maleate was assessed in 94 patients with acute myocardial infarction. No significant differences were noted between early treatment with timolol and placebo in the mean and peak hourly ventricular premature complex rates, ventricular premature complex couplets, or runs. However, compared to the placebo treatment, there was a significant ( p p p = 0.008). Adverse effects from early administration of timolol did not differ from those in the placebo-treated patients.